Baseline Demographics and Disease Characteristics from the ULTIMATE Phase III Trials Evaluating Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Multiple Sclerosis

被引：0

作者：

Steinman, Lawrence ^{[1
]}

Fox, Edward ^{[2
]}

Hartung, Hans-Peter ^{[3
]}

Cree, Bruce ^{[4
]}

Alvarez, Enrique ^{[5
]}

Qian, Peiqing ^{[6
]}

Wray, Sibyl ^{[7
]}

Robertson, Derrick ^{[8
]}

Huang, Deren ^{[9
]}

Selmaj, Krzystof ^{[10
]}

Wynn, Daniel ^{[11
]}

Weiss, Michael ^{[12
]}

Bosco, Jenna ^{[12
]}

Power, Sean ^{[12
]}

Mok, Koby ^{[12
]}

机构：

[1] Stanford Univ, Stanford, CA 94305 USA

[2] Cent Texas Neurol Consultants, Round Rock, TX USA

[3] Heinrich Heine Univ, Dusseldorf, Germany

[4] Univ Calif San Francisco, UCSF Weill Inst Neurosci, San Francisco, CA 94143 USA

[5] Univ Colorado, Boulder, CO 80309 USA

[6] Swedish Med Ctr, Englewood, CO 80110 USA

[7] Hope Neurol, Knoxville, TN USA

[8] Univ S Florida, Morsani Coll Med, Tampa, FL 33620 USA

[9] Mt Carmel Neurol, Westerville, OH USA

[10] Med Acad Lodz, Lodz, Poland

[11] Consultants Neurol Ltd, Northbrook, IL USA

[12] TG Therapeut, New York, NY USA

来源：

NEUROLOGY | 2020年 / 94卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

4845

引用

页数：4

共 50 条

[21] Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for Multiple Sclerosis: A Review of Clinical Considerations
William T. Barham
Kathryn M. Dillman
Joseph D. Hebert
Christian K. Kerut
Rachel J. Klapper
Shahab Ahmadzadeh
Sahar Shekoohi
Elyse M. Cornett
Alan D. Kaye
SN Comprehensive Clinical Medicine, 6 (1)
[22] A phase 1 trial of BCD-132, a novel anti-CD20 monoclonal antibody, in patients with remitting forms of multiple sclerosis
Boyko, O.
Zinkina-Orikhan, A.
Kotov, S.
Linkova, Y.
Prakhova, L.
Totolyan, N.
Shur, S.
Boyko, A.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 740 - 741
[23] Baseline Demographics and Disease Characteristics from ORATORIO, a Phase III Trial Evaluating Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis
Montalban, X.
Hemmer, B.
Rammohan, K.
Giovannoni, G.
de Seze, J.
Bar-Or, A.
Arnold, D.
Sauter, A.
Leppert, D.
Chin, P.
Garren, H.
Messier, M.
Wolinski, J.
Kakarieka, A.
Masterman, D.
EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 706 - 706
[24] Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial
Sharman, Jeff P.
Farber, Charles M.
Mahadevan, Daruka
Schreeder, Marshall T.
Brooks, Heather D.
Kolibaba, Kathryn S.
Fanning, Suzanne R.
Klein, Leonard M.
Sportelli, Peter
Miskin, Hari P.
Weiss, Michael S.
Greenwald, Daniel R.
BLOOD, 2014, 124 (21)
[25] The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
Stephen L. Hauser
Ludwig Kappos
Amit Bar-Or
Heinz Wiendl
David Paling
Mitzi Williams
Ralf Gold
Andrew Chan
Ron Milo
Ayan Das Gupta
Goeril Karlsson
Roseanne Sullivan
Gordon Graham
Martin Merschhemke
Dieter A. Häring
Patrick Vermersch
Neurology and Therapy, 2023, 12 : 1491 - 1515
[26] The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
Hauser, Stephen L.
Kappos, Ludwig
Bar-Or, Amit
Wiendl, Heinz
Paling, David
Williams, Mitzi
Gold, Ralf
Chan, Andrew
Milo, Ron
Das Gupta, Ayan
Karlsson, Goeril
Sullivan, Roseanne
Graham, Gordon
Merschhemke, Martin
Haring, Dieter A.
Vermersch, Patrick
NEUROLOGY AND THERAPY, 2023, 12 (05) : 1491 - 1515
[27] Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma; Results of a Phase II Trial
Kolibaba, Kathryn
Burke, John M.
Brooks, Heather D.
Mahadevan, Daruka
Melear, Jason
Farber, Charles M.
Fanning, Suzanne R.
Schreeder, Marshall T.
Boccia, Ralph V.
Sportelli, Peter
Miskin, Hari P.
Weiss, Michael S.
Sharman, Jeff P.
BLOOD, 2015, 126 (23)
[28] Demographics and baseline disease characteristics of patients with relapsing multiple sclerosis from Kenya participating in the CHIMES trial
Sokhi, D. S.
Hooker, J.
Williams, M. J.
Amezcua, L.
Shamshudin, A.
Hussein, Y. E.
Betti, P.
Amariati, H.
Karimi, N.
Gondi, S.
Pei, J.
Bulhan, H.
Okaka, D.
Acosta, J.
Saleh, M.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 841 - 841
[29] Effects of anti-CD20 monoclonal antibody therapy on cerebrospinal fluid B cell subsets in relapsing-remitting multiple sclerosis
El Mahdaoui, S.
Hansen, M. M.
von Essen, M.
Sellebjerg, F.
Christensen, J. Romme
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 840 - 840
[30] A phase I trial of ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody (mAb) in B-cell non-Hodgkin lymphoma patients with prior exposure to rituximab.
O'Connor, Owen A.
Deng, Changchun
Amengual, Jennifer Effie
Khalil, Mazen Y.
Schreeder, Marshall T.
Mahadevan, Daruka
Nikolinakos, Petros
Sawas, Ahmed
Zain, Jasmine M.
Patterson, Molly
Moon, Amber
Pauli, Emily K.
Cutter, Kathy
Mackenzie, Michelle Ann
Brotherton, Marnie
Hodgson, Jamie
Cooper, Christen N.
Sportelli, Peter
Miskin, Hari P.
Farber, Charles Michael
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

← 1 2 3 4 5 →